Here are some highlights from the Boston meeting. For more information about the European Conference, visit www.genetherapy-europe.com
Promising early clinical results have reinvigorated the gene therapy field. After decades of unfulfilled potential, this space is gaining tangible momentum, particularly in addressing the significant unmet need in a range of rare diseases.
Gene Therapy for Rare Disorders 2017 is the only conference devoted to overcoming the clinical, manufacturing, regulatory and commercialization hurdles holding back progress in this field.
Bringing together leading experts from innovative biotechs, large pharma, academia and key service provider companies, Gene Therapy for Rare Disorders will present a comprehensive insight into the cutting edge progress of gene therapies combatting rare disease.
Rather than replicating broad academic cell and gene therapy meetings, this conference will present in-depth case studies detailing how gene therapies can become commercially successful in ophthalmic, CNS, hepatic, muscular and many other rare disorders.
Enhance your gene therapy development by gaining insights on how to:
- Improve clinical development
- Navigate the regulatory pathway
- Scale up manufacturing from academic to commercial scale
- Overcome the pricing and reimbursement hurdles
Join your colleagues at Gene Therapy for Rare Disorders to accelerate the progress of the next generation of gene therapies that show improved efficacy, enhanced safety and commercial viability.
Email firstname.lastname@example.org for more information about the European conference in October 2017 or the Boston conference in April 2018.